FindTrial
Sign In

Data Collection project on patients with severe sepsiswho received injection named Ulinastatin

Outcome of patients with severe sepsis who received Ulinastatin (U-Tryp) therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/03/004470
Enrollment
134
Registered
2014-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Sepsis

Interventions

Intervention1: Utryp: Ulinastatin is a serine protease inhibitor that reduces the pro-inflammatory response as a result of sepsis acute pancreatitis, trauma or surgery. Ulinastatin for Injection is av

Sponsors

MedantaThe medicity
Lead Sponsor
Bharat Serum and Vaccines ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients admitted in ICU were assessed and included if they were 18 yrs old and full fill the criteria of severe sepsis (Sepsis with organ dysfunction or tissue hypoperfusion).

Exclusion criteria

Exclusion criteria: Terminally ill patients Acute Myocardial infarction CVA Hypersensitivity to U-trip Chronic treatment with immuno suppressive drugs

Design outcomes

Secondary

MeasureTime frame
Recovery from the sepsis organ dysfunction length of ICU stay need for ventilatory and inotropic support.Timepoint: 10 months—

Primary

MeasureTime frame
ICU mortality in severe sepsis patientsTimepoint: 10 months—

Countries

India

Contacts

Public ContactDrAshish Kumar

Medanta-The Medicity

kumarsxn@yahoo.com91-9818741361

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026